Details of the Drug

General Information of Drug (ID: DMRCLZB)

• Drug Name: Pentagastrin
• Synonyms: Peptavlon; Peptavlon (TN); Pentagastrin (JAN/USAN/INN); (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[3-(2-methylpropoxycarbonylamino)propanoylamino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid

Indication

Disease Entry	ICD 11	Status	REF
Diagnostic imaging	N.A.	Approved	[1]

• Therapeutic Class: Diagnostic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 3:
  Molecular Weight (mw); 767.9
  Logarithm of the Partition Coefficient (xlogp); 1.5
  Rotatable Bond Count (rotbonds); 22
  Hydrogen Bond Donor Count (hbonddonor); 8
  Hydrogen Bond Acceptor Count (hbondacc); 10
• ADMET Property:
  Absorption: The drug is rapidly absorbed after parenteral administration []
  Half-life: The concentration or amount of drug in body reduced by one-half in less than 10 minutes [2]
  Metabolism: The drug is metabolized via the hepatic []
• Chemical Identifiers:
  Formula: C37H49N7O9S
  IUPAC Name: (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoylamino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid
  Canonical SMILES: CC(C)(C)OC(=O)NCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N
  InChI: InChI=1S/C37H49N7O9S/c1-37(2,3)53-36(52)39-16-14-30(45)41-28(19-23-21-40-25-13-9-8-12-24(23)25)34(50)42-26(15-17-54-4)33(49)44-29(20-31(46)47)35(51)43-27(32(38)48)18-22-10-6-5-7-11-22/h5-13,21,26-29,40H,14-20H2,1-4H3,(H2,38,48)(H,39,52)(H,41,45)(H,42,50)(H,43,51)(H,44,49)(H,46,47)/t26-,27-,28-,29-/m0/s1
  InChIKey: NEYNJQRKHLUJRU-DZUOILHNSA-N
• Cross-matching ID:
  PubChem CID: 9853654
  ChEBI ID: CHEBI:31974
  CAS Number: 5534-95-2
  DrugBank ID: DB00183
  TTD ID: D0O5TQ

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gastrin/cholecystokinin type B receptor (CCKBR)	TTVFO0U	GASR_HUMAN	Agonist	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Insulin (INS)	OTZ85PDU	INS_HUMAN	Protein Interaction/Cellular Processes	[4]
Pro-opiomelanocortin (POMC)	OTV41F7T	COLI_HUMAN	Gene/Protein Processing	[5]
Secretin (SCT)	OTV3MLOO	SECR_HUMAN	Drug Response	[6]

Molecular Expression Atlas of This Drug

• The Studied Disease: Diagnostic imaging
• ICD Disease Classification: N.A.

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Gastrin/cholecystokinin type B receptor (CCKBR)	DTT	CCKBR	6.53E-01	1.00E-03	4.05E-03

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 870).
• [2] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [3] Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. Neuropsychopharmacology. 2009 Jan;34(2):509-21.
• [4] Anxiogenic effects of the CCK(B) agonist pentagastrin in humans and dose-dependent increase in plasma C-peptide levels. Psychopharmacology (Berl). 2002 Jun;161(4):396-403. doi: 10.1007/s00213-002-1044-z. Epub 2002 Apr 17.
• [5] Dose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin. Neuropsychopharmacology. 1999 Oct;21(4):485-94. doi: 10.1016/S0893-133X(98)00124-9.
• [6] Secretin inhibits canine gastric acid secretion in response to pentagastrin by modulating gastric histamine release. J Pharmacol Exp Ther. 1996 Nov;279(2):718-23.